Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials. MRBs exert antihypertensive and cardiorenal protective effects, and their potency is thought to be far superior to that of MRAs, because MRBs have both strong MR inhibitory action and high selectivity. Thus, MRBs could be a promising agent for the treatment of hypertension and cardiorenal, cerebral, and metabolic disorders.
Authors: Daisuke Sueta, Eiichiro Yamamoto, Kenichi Tsujita
Keywords: mineralocorticoid receptor antagonists (MRAs), MR blockers (MRBs)
DOI Number: 10.1007/s11906-020-1023-y Publication Year: 2020
To search for other research papers by topic, keyword, author, or year, please go to our Publications page.